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Abstract Human hepatocarcinoma cells (SK-HEP-I) were in- 
duced to die through apoptosis by treatment with A12-prosta - 
glandin (PG)J2, as characterized by the appearance of a typical 
DNA ladder. The induction of apoptosis by A~2-PGJ2 was specif- 
ically blocked by cycloheximide (CHX). Western analysis using 
anti-p53 or anti-WAFl monoclonal antibodies demonstrated that 
these two protein levels were increased 3 h after A12-pGJ2 treat- 
ment, and accumulated for up to 12 h. The induction of p53 
protein seemed to be dependent on the increase of p53 mRNA 
level, which was inhibited by CHX treatment. However, delayed 
addition of CHX after A~2-pGJ 2 treatment failed to affect both 
p53 mRNA levels and DNA fragmentation following A12-pGJ 2 
treatment, indicating that the inhibition of p53 synthesis may 
contribute to the protective effect of CHX against A12-pGJ 2- 
mediated cytotoxicity. Therefore, our results suggest that the 
initial events caused by A12-pGJ 2, leading ultimately to SK-HEP- 
1 cell death, involve a certain process required for p53 induction. 
However, the finding that A12-pGJ2 is also active against Hep 3B 
cells which are devoid of a functional p53 indicates that p53 may 
not be the critical requirement for inducing apoptosis by A 12- 
PGJ 2. 
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ability to repair or delete the DNA-damaged cells, which con- 
tributes to the development and progression of cancer [11,12]. 
In addition, p53 status is expected to affect the outcome of 
cellular esponse after exposure to cytotoxic agents [10,13]. The 
growth inhibitory activity of p53 is apparently mediated by 
transcriptional ctivation of several genes involved in cell pro- 
liferation such as WAF1/CIP1 and GADD [14-17]. 
To determine the involvement of p53 in AJ2-PGJ2-induced 
apoptosis, we investigated the change of p53 as well as WAFI 
levels following 312-pGJ 2 treatment in relation to the induction 
of apoptosis in human hepatocarcinoma SK-HEP-1 cells which 
are reported to have wild-type p53 [18]. We also examined the 
effects of cycloheximide (CHX) on the induction of apoptosis 
and p53 accumulation by A~z-PGJ 2 treatment. 
2. Materials and methods 
2.1. Reagents 
A~2-PGJ2 was kindly supplied by Ono Pharmaceutical Co. (Osaka, 
Japan) and a stock solution (10 mg/ml) was prepared in 95% ethanol. 
Cycloheximide (CHX), actinomycin D (Act-D), proteinase K and 
RNase A were purchased from Sigma (St. Louis, MO) and DNA size 
markers were obtained from Gibco BRL (Gaithersburg, MD). All 
other chemicals used were of reagent grade. 
I. Introduction 
A12-pGJ2, one of the cyclopentenone PGs containing an un- 
saturated carbonyl group, has been reported to have potent 
growth inhibitory and differentiation inducing activities in 
some tumor cells [1-3]. It has been shown that AI2-PGJ2 is 
actively transported to nuclei and binds to nuclear proteins 
[4,5], and binding of the PG molecule to nuclear proteins ap- 
pears to regulate the expression of specific genes which are 
responsible for growth inhibition [6]. Recently, we have re- 
ported that cyclopentenone PGs cause cell death via an apop- 
totic pathway in murine leukemia L1210 cells, which was pre- 
ceded by cell cycle arrest in G2/M and dependent upon protein 
synthesis [7]. Thus, DNA damage and specific gene expression 
seemed to be involved in A~2-PGJ2-mediated apoptosis. How- 
ever, the molecular mechanisms by which A~2-PGJ 2 lead cells 
to apoptotic ell death has not yet been determined. 
p53, a nuclear phosphoprotein, is the product of a tumor 
suppressor gene which is related to cellular response to DNA 
damage resulting in cell cycle arrest or induction of apoptosis 
[8 10]. Thus, loss of normal p53 function may abolish the 
*Corresponding author. Fax: (82) (2) 596-4435. 
2.2. Celia' and treatment protocols 
Human hepatocarcinoma SK-HEP-1 cells and Hep 3B cells were 
obtained from American Type Culture Collection (ATCC, Rockville, 
MD) and maintained in RPMI 1640 medium containing 10% heat- 
inactivated fetal bovine serum and 50 ,ug/ml of gentamicin. Cells were 
plated at a density of 1 × 105/ml on a 96-well microtiter plate or a 6-well 
culture plate in 100 pl or 1 ml of medium, respectively, and incubated 
with various agents for the indicated times. In some experiments, CHX 
was added to each well at the specified times after A~2-PGJ 2treatment, 
and incubation was continued for the remaining period before the 
assessment of DNA fragmentation r p53 induction. 
2.3. Cell viability and assessment ofapoptotic DNA fragmentation 
Cell viability was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide (MTT) method [19]. DNA integrity in 
SK-HEP-I cells undergoing apoptosis was evaluated by agarose gel 
electrophoresis followed by ethidium bromide staining. Cells were lysed 
and digested overnight at 48°C in lysis buffer (10 mM Tris-HC1, pH 
7.4, 10 mM EDTA, 10 mM NaCI and 0.5% SDS) containing proteinase 
K (100 pg/ml). A 1/5 volume of 5 M NaC1 and an equal volume of 
isoamyl alcohol were added to precipitate DNA. The DNA pellet was 
redissolved in TE buffer (10 mM Tris-HC1, pH 7.8, 1 mM EDTA) and 
treated with RNase A (0.1 mg/ml) for 4 h at 37°C prior to 1.5% agarose 
gel electrophoresis. 
Quantification ofDNA fragmentation was determined by detection 
of 5-bromo-2'-deoxy-uridine (BrdU)-labeled DNA fragments in the 
cytoplasm of SK-HEP-1 cells [20] using a cellular DNA fragmentation 
ELISA kit (Boehringer-Mannheim, Mannheim, Germany). Morpho- 
logical analysis of the cells undergoing apoptosis was performed by 
Giemsa staining. 
Abbreviations." PG, prostaglandin; CHX, cycloheximide; Act-D, actino- 
mycin D. 
2.4. Western blot analysis 
For immunoblots, 1 × 105 cells were lysed in Laemmli ysis buffer [21] 
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and cellular proteins were separated by 10% sodium dodecylsulfate- 
polyacrylamide g l electrophoresis (SDS-PAGE) and then electroblot- 
ted onto nitrocellulose papers. After blocking with 5% non-fat milk in 
phosphate buffered saline, the papers were incubated with a mouse 
monoclonal antibody against human p53 (Ab-2; Oncogene Science, 
Cambridge, MA) or human WAF1/CIP1 (Ab-1; Oncogene Science) for 
1 h at room temperature. Proteins were revealed by enhanced chemilu- 
minescence system (Amersham, Buckinghamshire, UK) using horse- 
radish peroxidase-conjugated goatanti-mouse immunoglobulin G as a 
secondary antibody. 
2.5. Northern blot analysis 
Total RNA was extracted from cells using a commercial system 
provided by Amresco (Solon, OH). Equal amounts of RNA were elec- 
trophoresed through 1% formaldehyde agarose gels and then trans- 
ferred onto nylon filters. The blots were hybridized with digoxigenin 
(DIG)-labeled specific DNA probes overnight at 50°C. p53 and fl-actin 
cDNA probes were prepared by polymerase chain reaction with DIG- 
I1-UTP (Boehringer-Mannheim) using specific primers provided by 
Clontech (Palo Alto, CA). The blots were washed and incubated with 
alkaline phosphatase-conjugated anti-DIG antibody and then the hy- 
bridized probes were immunodetected with chemiluminescent substrate 
supplied by Boehringer-Mannheim. 
3. Results 
When SK-HEP-I cells were incubated with 5 #g/ml of A ~2- 
PGJ2, cells began to lose viability after 24 h as determined by 
the MTT method (Fig. 1A), whereas morphological changes 
representative of apoptosis uch as loss of cell-cell contact, 
chromatin condensation a d reduction of cytoplasmic volume 
appeared as early as 6 h after treatment (data not shown). The 
quantitative assay of BrdU-labeled DNA fragments demon- 
strated that DNA fragmentation significantly increased within 
24 h ofdl2-pGJz incubation (Fig. 1B), concurrent with the loss 
of viability. 
Electrophoretic analysis of total cellular DNA isolated from 
zf2-pGJ2-treated SK-HEP-1 cells revealed a pattern of internu- 
cleosomal DNA cleavage, which is specific for apoptosis (Fig. 
2). Fig. 2 also shows that the induction of ladder DNA was 
completely blocked by a protein synthesis inhibitor, CHX. 
To assess the involvement of p53 in d12-pGJ2-mediated apop- 
tosis, p53 expression i  the SK-HEP-1 cells following A12-pGJ2 
treatment was examined. Western blot analysis demonstrated 
that p53 levels began to increase at 3 h and remained high for 
up to 12 h after treatment (Fig. 3A). We also observed the 
induction of WAF1, a critical downstream ediator of p53- 
dependent apoptosis, with the increase in the levels of p53 (Fig. 
3A). It appears that the accumulation of p53 protein after 
A j2-PGJ 2 treatment is dependent on the increase of p53 mRNA 
levels as seen in Fig. 3B, rather than on a post-transcriptional 
mechanism which was suggested in other cells treated with 
Act-D or UV [8,22]. We then examined the effect of CHX on 
the induction of p53, WAF1 and p53 mRNA, since CHX was 
shown to completely block DNA fragmentation caused by A j2- 
PGJ2 in Fig. 2. Fig. 4 shows that the elevated expression of p53 
(and subsequently WAF1) as well as p53 mRNA, which were 
induced by A12-pGJ2 treatment, were completely prevented by 
CHX. These results indicate that the protective ffect of CHX 
on A~2-PGJ2-induced apoptosis may be due to the inhibition of 
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cells following A -PGJ2 treatment. SK-HEP-I cells were incubated with Fig. 1. Kinetics of cell death (A) and DNA fragmentation (B)in SK-HEP-1 . ~2 
5 #g/ml of A~LPGJ2 in a 96-well microtiter plate in triplicate for the indicated times and the viability was assessed by the MTT methods (A). DNA 
fragmentation was analyzed by evaluating the presence of BrdU-labeled DNA fragments as described in section 2 (B). 
350 J.-H. Lee et al . /FEBS Letters 368 (1995) 348 352 
p53 induction, and that p53 mRNA accumulation after d j2- 
PGJ2 treatment is evidently an active process requiring the 
synthesis of new proteins. 
To investigate further the relationship between p53 expres- 
'n 12 sion and the apoptotic response follow] g A -PGJ2 treatment, 
CHX was added at various times. Incubation was continued for 
a total of 9 h for assessment of p53 mRNA expression or for 
48 h for analysis of DNA fragmentation respectively. As shown 
in Fig. 5, only when added simultaneously or 1 h after A~2-PGJ2 
treatment, CHX was able to block both the apoptosis and p53 
mRNA accumulation. Addition of CHX 3 h after A~2-PGJ2 
treatment, at which time p53 mRNA levels were not shown to 
be affected (Fig. 5A), failed to prevent subsequent apoptotic 
cell death (Fig. 5B). These results, taken together, suggest that 
p53 may play a role in initiating the apoptotic response of 
SK-HEP-1 cells exposed to A~Z-PGJ2, and that the increase in 
p53 mRNA is regulated by certain proteins which were induced 
sufficiently within 3 h after AJ2-pGJ2 treatment. 
In Fig. 6 we observed that Act-D also induced p53 and 
WAF1 protein expression as well as a clear ladder pattern in 
SK-HEP-1 cells, all of which were suppressed by CHX. In 
contrast, northern blot analysis of total RNA from Act-D 
treated SK-HEP-I cells revealed no significant change in p53 
mRNA levels (data not shown) indicating that Anz-pGJ 2 and 
Act-D induce p53 expression by different mechanisms. 
To determine whether A~2-PGJ2 induces apoptosis only 
through a p53-dependent pathway as suggested above, we ex- 
amined DNA integrity after A~2-pGJ 2 treatment in Hep 3B cells 
in which the p53 transcripts were not detected ue to a large 
deletion of p53 gene [18]. In Fig. 7 DNA from Hep 3B cells 
treated with a higher concentration (10/,tg/ml) of AI2-pGJ 2 
presented a typical adder pattern, which was also blocked by 
CHX treatment, suggesting that A~Z-PGJ2-induced apoptosis i
not wholly dependent upon p53 induction. 
1 2 3 4 5 
Fig. 2. Electrophoretic analysis of DNA from SK-HEP-1 cells. DNA 
was analyzed on a 1.5% agarose gel and stained with ethidium bromide. 
Cells were treated as follows: Lanes: 1 = 123 DNA size marker; 2 = un- 
treated control cells; 3 = cells incubated with 1/zg/ml ofCHX; 4 = cells 
incubated with 5/~g/ml of zI~2-pGJ2; 5= cells incubated with 5/zg/ml 
ofAJ2-PGJ 2 in the presence of 1/tg/ml of CHX for 48 h. 
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Fig. 3. Levels of p53 and WAF1 proteins (A) and p53 mRNA (B) 
following AJ2-PGJ2 treatment. (A) Immunoblot analysis of p53 and 
WAF1 proteins. Total cellular proteins from 1 x l0 s cells were sub- 
jected to SDS-PAGE at the indicated times after exposure to 5/lg/ml 
of A~2-PGJ2. p53 positive bands were revealed by an indirect immuno- 
peroxidase method using enhanced chemiluminescence detection rea- 
gents as described in section 2. (B) Northern blot analysis of p53 
mRNA. RNA was isolated from each preparation a d electrophoresed 
through aformaldehyde agarose gel. The transferred RNA was hybrid- 
ized with DIG-labeled probes for p53 and fl-actin and processed for 
detection as described in section 2. 
4. Discussion 
It has been shown that expression ofwt p53 leads cells to G1 
arrest or apoptotic ell death in response to a variety of DNA 
damaging agents including UV irradiation, Act-D and topoi- 
somerase inhibitors [8,23]. The results presented in this paper 
raised the possibility that p53 induction is involved in AI2-PGJ2 - 
mediated apoptosis in SK-HEP-I cells. Our results show that 
p53 and WAFI/CIP1 levels were increased by d12-pGJ 2 with 
incubation time and attenuated by CHX, correlating with the 
protective activity of CHX against apoptotic death. But the 
molecular details of the induction of DNA damage and subse- 
quent p53 expression by A12-PGJ2 remain to be elucidated, 
although the ~, fl-unsaturated carbonyl moiety was suggested 
to be required for the biological activities of the cyclopentenone 
PGs [24 26]. However, the manner in which A12-pGJ 2 increased 
p53 levels did not seem to be shared with Act-D or UV damage 
in that A~2-PGJ 2 primarily increased p53 mRNA levels, whereas 
Act-D or UV caused an accumulation of p53 protein without 
detectable changes in p53 mRNA expression, as shown in our 
experiments and previous reports [8,22]. 
Our results also demonstrated that active synthesis of certain 
proteins is necessary to elevate the level of p53 mRNA, thereby 
initiating apoptosis in SK-HEP-1 cells treated with AI2-PGJ2. 
The requirement of protein synthesis for PG cytotoxicity has 
been suggested by several investigators [27,28] and it was also 
shown that the cyclopentenone PGs altered protein synthesis 
patterns howing induction or suppression of specific proteins 
in some cells [29,30]. However, any associations between these 
PGs-induced proteins and the cytotoxic effect of PGs are not 
yet established. Here we have shown that the proteins which 
were induced and accumulated before 3 h following At2-PGJ2 
treatment may be essential for inducing apoptosis in our sys- 
tem, probably by participating in the increase in p53 mRNA, 
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Fig. 4. Inhibition ofAL2-PGJ2-induced p53/WAFl expression by CHX. 
SK-Hep-I cells were incubated with 1 pg/ml of CHX (lane 2), 5/lg/ml 
of A~2-PGJ2 alone (lane 3), or both agents (lane 4) for 9 h and then 
processed for detection of p53 and WAF1 proteins (A) or p53 and 
fl-actin mRNA (B) as in Fig. 3. Lane 1 represents he results from 
control cells. 
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Fig. 5. Delayed addition of CHX after AJ2-pGJ2 treatment failed to 
prevent the induction of apoptosis and p53 mRNA. SK-HEP-1 cells 
were incubated without (lane 1) or with 5 ,ug/ml of AL2-PGJ2 (lane 2). 
CHX (1 ,ug/ml) was added at 0, 1, 3, 6 and 9 h (lane 3-7, respectively) 
after AI2-PGJ2 treatment. After 9 h of total incubation, the p53 mRNA 
level was determined byNorthern analysis (A) and DNA fragmentation 
was also assessed by agarose gel electrophoresis after 48 h of total 
incubation (B). 
Fig. 6. Induction of DNA fragmentation a d expression of p53 and 
WAFI proteins in SK-HEP-1 cells by Act-D. Sk-HEP-1 cells were 
treated Act-D alone (lane 2) or Act-D plus CHX (lane 3) for 48 h and 
then analyzed for DNA fragmentation as in Fig. 2. (A) The expression 
of p53 and WAF1 proteins were determined by western blotting after 
9 h of incubation (B). Lane 1 shows the results from untreated control 
cells. 
since CHX addition later than 3 h could neither protect cells 
from entering apoptotic death nor prevent the increase in p53 
mRNA. 
It is likely, therefore, that the d ~2-PGJE-induced proteins may 
function as transcriptional activators of p53. It has been shown 
that the p53 promoter is activated by several proteins uch as 
NF-xB, c-myc and p53 itself [31 34]. In addition, NF-xB and 
c-myc were reported to be induced by DNA damage [35,36]. 
Thus, we can postulate that one of these p53 transactivator 
proteins may be a candidate for the d~2-PGJ2-induced protein, 
or may be activated indirectly by a newly synthesized protein 
after A12-PGJ2 treatment. However, the possibility that the zf 2- 
PGJ2-induced proteins may be involved in the stabilization of 
p53 mRNA, rather than in transactivation, can not be excluded 
at present. 
Despite the correlation of induction between p53 and apop- 
tosis in SK-HEP-1 cells, p53 seems not to be the critical deter- 
minant of d~2-PGJ2-induced apoptosis, considering that d ~2- 
PGJ2 also induced apoptosis in Hep 3B cells devoid of a func- 
tional p53. An alternative apoptotic pathway, therefore, may 
be also activated by AI2-pGJ2 to initiate the cell death program, 
where continued protein synthesis still indispensable. Other- 
wise, p53 induction may be an accompanying phenomenon f 
some early events induced by AI2-PGJ2, which involve specific 
protein synthesis and eventually lead to apoptotic ell death 
irrespective ofp53 status. Either p53 expressing or p53 deficient 
cells, anyhow, obviously require specific protein synthesis for 
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Fig. 7. Analysis of DNA fragmentation in Hep 3B cells exposed to 
A~2-pGJ2 . Hep 3B cells were exposed to 10/lg/ml ofAI2-PGJ 2 alone (lane 
2) or in the presence of 1 pg/ml of CHX (lane 3) for 48 h prior to 
assessment of DNA by 1.5% agarose gel electrophoresis. Lane 1 is 
DNA from untreated control cells. 
apoptosis induction, although it is not certain whether the same 
protein is involved in both cells. Therefore, further investiga- 
tions aimed at identifying a newly synthesized protein by A 12- 
PGJ2 and its subsequent targets, if present, will provide more 
comprehensive understanding of the exact mechanism through 
which AIZ-PGJ2 induced apoptosis. 
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